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Summary 
Fibrin deposition is a common accompaniment of renal allograft rejection, indicating disruption 
of the normal physiologic balance between procoagulant and anticoagulant pathways. In vitro, 
tumor necrosis factor (TNF) induces endothelial expression of the procoagulant,  tissue factor, 
and downregulation of thrombomodulin, a key component of the thrombomodulin/protein C 
(PC)/protein S (PS) pathway, which normally maintains an anticoagulant state by inactivating 
thrombin, preventing further thrombin formation by degrading factors Va and VIIIa, and decreasing 
plasminogen activator inhibitor activity. Raised levels  of TNF were recently demonstrated within 
the blood of patients  during episodes of renal allograft injection, and may be an early and 
discriminatory marker of rejection. This led us to investigate prospectively whether monitoring 
of serum TNF levels was of value dinically, and was associated with effects on circulating PC 
and PS levels, or alterations in intragraft thrombomodulin expression. Plasma samples (n = 454) 
were collected three times/week from all patients  (n  =  25) undergoing renal transplantation 
during a 9-month consecutive period, and assayed  by ELISA and functional assays for TNF, PC, 
and free PS (FPS). Portions of renal biopsies, taken to evaluate episodes of acute deterioration 
of renal function, were evaluated by immunoperoxidase labding for the presence and distribution 
of TNF, thrombomodulin, PC, PS, thrombin, fibrin, and factors V and VIII. Comparison of 
78 plasma samples collected during 26 episodes of biopsy-proven acute cellular rejection with 
samples collected during periods of stable renal function (n  =  349) showed that TNF levels 
rose significantly (390  +_  242 pg/ml, p <  0.01) above background levels 3 days before rising 
serum creatinine concentrations, and peaked (2,426 _+ 978 pg/ml) on the day of clinical rejection. 
PC-antigen (Ag) concentrations also decreased 3 days before rejection (68  _+  13%, p < 0.05), 
and were maximally depressed (49%  _+  16%, p <  0.001) on the day of rejection. FPS levels 
were normal until the day before rejection (63% +_ 8%, p < 0.01) and, like PC, were maximally 
depressed (43 +  10%) at rejection. Plasma TNF levels  were significantly and inversely correlated 
with PC-Ag (p < 0.001) and FPS (p < 0.005) levels during rejection, regardless of whether such 
rejection episodes were steroid responsive or required OKT3 monoclonal antibody therapy. TNF, 
PC, and FPS levels were normal during episodes of cydosporine toxicity and viral infection. 
Immunoperoxidase  studies showed that rejection was associated with a intrarenal production 
of TNF, decreased microvascular labeling for thrombomodulin, and widespread endothelial and 
interstitial deposition of PC, PS, thrombin, fibrin, and factors V and VIII. These findings suggest 
that TNF is an important mediator of renal allografr rejection, causing depression of the intragraft 
thrombomodulin/PC/PS pathway  and thereby  contributing to intragraft  fibrin  deposition. 
Moreover, these results indicate that monitoring of circulating concentrations of TNF, PC, and 
FPS has rdevance to the early detection and differential diagnosis of human acute renal allograft 
rejection. 
H 
uman acute interstitial  renal allograft rejection is as- 
sociated  with  progressive  graft  infiltration  by 
mononudear cells, particularly macrophages, CD8 + T cells, 
and lesser numbers of CD4 + T cells (1, 2). Some 10-20% 
of interstitial mononuclear cells present in renal biopsies taken 
at the time of rejection show features of immune activation 
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molecule, tissue factor (3, 4). Intragraft macrophage and en- 
dothelial expression of tissue factor are associated  with ex- 
tensive local fibrin deposition, whereas CD25,  tissue factor 
expression, and widespread fibrin deposition are not present 
in biopsies from patients with cyclosporin toxicity or normal 
renal function posttransplantation (3, 4). A pivotal role for 
these IL-2R + mononuclear cells in mediating kidney rejec- 
tion is demonstrated by the successful treatment or, in some 
cases, prevention of allograft rejection in clinical (5) and ex- 
perimental (6,  7)  studies using CD25  mAbs. 
How allograft rejection occurs, once immune activation 
has taken place, is still only understood in very broad terms. 
An increasing number of cytokines, whose production and 
actions are known largely through in vitro studies, are im- 
plicated by monitoring peripheral blood or urine samples from 
renal transplant recipients undergoing episodes of allograft 
rejection. These include TNF (8), Ibl (9), I1.-2 (10) and its 
corresponding IL-2R (11), and IL-6 (12). However, with the 
exception of Ib2,  whose suppression of production by cy- 
closporin is considered central to current immunosuppres- 
sive therapy (13), the contribution and relative importance 
of such cytokines to the rejection process in vivo are unknown. 
TNF, produced by activated macrophages and to a lesser 
extent, activated T and B cells, is a pleiotropic cytokine in- 
volved in host defenses against parasitic infections and tumors, 
and mediation of septic shock (14). We have focused on the 
potential role of TNF as an effector molecule in renal allograft 
rejection for several reasons.  First,  TNF,  at least in vitro, 
profoundly alters the thrombogenicity of endothelial ceils by 
inducing expression of procoagulant molecules (15) and down- 
regulating expression of thrombomodulin (16), a key com- 
ponent of the physiologically potent thrombomodulin/pro- 
tein C  (PC)l/protein  S (PS) anticoagulant system (17).  In 
addition, TNF induces endothelial expression of leukocyte 
adhesion molecules (18, 19), production of IL-1 (20, 21) and 
IL-6 (22),  and upregulation of the density of class I MHC 
antigens (23). Second, recent studies in rats have shown that 
intragraft mononuclear cells produce TNF  in vivo during 
acute kidney rejection (7), and that anti-TNF antibodies pro- 
long allograft survival (24). Last, immunohistologic and func- 
tional studies of cardiac allografts in untreated rats showed 
that TNF production by activated (Ib2R +) intragraft mono- 
nuclear cells was associated with local downregulation of 
thrombomodulin expression, induction of tissue factor ex- 
pression, and widespread intragraft fibrin deposition, whereas 
these features were absent in allografted rats that were treated 
with cyclosporin and showed long-term graft survival (25). 
Hence, many of the actions attributable to TNF in vitro ap- 
peared to be also demonstrable in vivo during allograft re- 
jection. 
The current study determined the levels of TNF, PC, and 
PS within serial blood samples from renal transplant recipients 
during the first 2-3 wk posttransplantation. In addition, di- 
1  Abbreviations used in this paper." Ag, antigen; FPS, free protein S; PC, 
protein C; PS, protein S. 
agnostic renal biopsies  taken during episodes of deteriora- 
tion in renal function were evaluated by immunoperoxidase 
labeling for endothelial expression of thrombomodulin, and 
deposition of PC,  PS, and fibrin.  The results demonstrate 
the clinical relevance of TNF as a mediator of human renal 
allograft rejection. 
Materials and Methods 
Patients and Immunosuppressive Therat,  /  All adult patients un- 
dergoing renal transplantation at Prince Henry's Hospital over nine 
consecutive months were studied prospectively. Patients received 
1 g of  methylprednisolone at the time of surgery, and were initially 
immunosuppressed according to a standard "induction therapy" 
protocol consisting of prophylactic OKT3 mAb (5 mg/d i.v., for 
7-10 d, beginning on the day of transplantation), plus azathioprine 
(0.5 mg/kg/d) and prednisolone (20 rag/d). Patients thereafter re- 
ceived triple therapy with cyclosporin, azathioprine, and predniso- 
lone. Azathioprine was increased to 2 mg/kg/d upon cessation of 
OKT3 mAb treatment, steroid therapy was maintained indefinitely, 
and cyclosporin was introduced, once serum creatinine levels had 
fallen to <250 #M, initially at a dose of 8 mg/kg/d, and thereafter 
according to the results of cyclosporin trough whole-blood ILIA. 
Rejection episodes were treated for 3 d with pulse doses of intrave- 
nous methylprednisolone (0.5 g/d), followed, if steroid unrespon- 
sive, by a 10-14-d course of OKT3 mAb (5 mg/d i.v.). Cyclosporin 
was discontinued during OKT3 mAb treatment and was recom- 
menced 2 d before cessation of mAb therapy. 
Blood Samples.  Citrated plasma samples were collected three 
times/wk beginning at the time of transplantation, and contin- 
uing throughout the period of  hospitalization, as well as at weekly 
outpatient follow-up sessions for 3 mo postdischarge. Plasma was 
isolated promptly by centrifugation, coded, and stored in aliquots 
at  -80~  A normal plasma pool was prepared by collection of 
citrated plasma from 10 healthy lab staff (six males, four females) 
not receiving anticoagulant or other medication.. 
Tissue Samples.  Episodes  of deterioration of renal function, in 
conjunction with clinical suspicion of rejection, were evaluated  by 
renal biopsy. Biopsy cores were divided into portions that were: 
(a) formalin fixed and paratfin embedded, for standard light mi- 
croscopy  and immunoperoxidase  analysis  of  immune reactants (Clq, 
C3,  IgA,  IgG,  IgM, fibrinogen), or (b) fixed at 4~  in para- 
formaldehyde-lysine-periodate  (26), washed overnight in PBS/7% 
sucrose, and quick frozen in liquid nitrogen, with storage at -80oC, 
before immunoperoxidase studies on cryostat sections, as detailed 
below. Control normal tissues (n = 4) were obtained from unused 
donor kidneys or kidneys resected for localized tumors. Portions 
of kidneys showing severe interstitial and/or vascular rejection (n 
== 4), obtained after transplant nephrectomy for eudstage rejec- 
tion,  were used as positive control tissues. 
Antibodies.  Paroxidase-conjugated and  unconjugated  rabbit 
anti-human PC and PS antibodies, plus peroxidase-conjugated  rabbit 
anti-mouse Ig and swine anti-rabbit  Ig, rabbit anti-human yon 
Willebrand factor, and rabbit anti-human fibrinogen/fibrin were 
obtained from Dako (Sydney,  Australia). Rabbit anti-human TNF 
was obtained from Genzyme (Boston, MA). mAbs and rabbit poly- 
clonal antibodies to human PC, PS, thrombomodulin,  factor V, 
and thrombin were prepared by Prof. H. Salem (Monash Univer- 
sity, Melbourne, Australia). Additional gifts ofmAbs included mAb 
to the activation peptide of PC (PC-121) (27), from Prof. F. Walker 
(American Red Cross, Farmington, CT); mAb to crosslinked  fibrin 
(T2G1), from Dr. B. Kudryk (The New York Blood Center, New 
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(Melbourne University, Parkville, Australia). Production and use 
of  PHM5, a mAb that gives  dense  labeling  of  all renal endothdium, 
as well as glomerular podocytes, in normal and rejecting kidneys, 
were described previously (29). 
TNF Bioassa  7 and ELISA.  TNF levels in patient plasma samples 
were measured  using the L929 fibroblast  cytotoxicity  bioassay  (30), 
in the presence of actinomycin-D (Sigma Chemical Co., St. Louis, 
MO), and plates were stained with coomassie  blue and their absor- 
bance read at 540 nm. Samples containing significant bioactivity 
(> 100 pg/ml) were evaluated  using a capture ELISA. Briefly,  mi- 
crotiter trays (Nunc, Sydney,  Australia)  were coated overnight with 
anti-TNF mAb (10 ~g/ml), blocked with 5% powdered milk, and 
incubated successively  with patient samples, rabbit anti-human 
TNF,  swine anti-rabbit  Ig-peroxidase conjugate, and o-phenyl- 
enediamine  dihydrochloride  (OPD) substrate (Sigma  Chemical  Co.); 
absorbances were read at 490 nm. Results in both assays  were ex- 
pressed as picograms per milliliter, calculated by the ELISA reader 
(MR-5000; Dynatech, Sydney, Australia) from a standard curve 
generated using serial dilutions of human r-TNF (Genzyme). The 
sensitivity of each method was 20 pg/ml, and the results achieved 
by bioassay  and ELISA  were highly correlated (r = 0.83, n = 126). 
Protein C ELISA and Amidolytic Assay.  PC antigen was mea- 
sured using a capture ELISA,  whereby microtiter trays were coated 
overnight with rabbit anti-human PC antibody, blocked with 5% 
powdered milk, and incubated successively  with patient or normal 
pooled plasma (diluted 1:100 in PBS/0.1% Tween-20), peroxidase- 
conjugated rabbit anti-human PC, and OPD substrate. To assess 
whether alterations in PC antigen  levels were associated with 
decreased PC function, PC amidolytic activity was determined by 
chromogenic assay (31), using an Actichrome PC kit (American 
Diagnostica, Sydney,  Australia). Briefly,  this involved  activation of 
plasma PC  by Protac, derived from  the venom of Agkistrodon 
contortrix, and measurement of cleavage (absorbance at 405 nm) 
of the activated PC-specific substrate, Spectrozyme, with or with- 
out addition of a neutralizing antibody to PC. Both assays were 
performed in triplicate and their results, expressed as a percent 
of normal pooled plasma, were highly correlated (r  =  0.90, n 
=  48). 
Protein S ELISA.  Unseparated  plasma samples were assayed  for 
total PS, and supernatants remaining after precipitation with poly- 
ethylene glycol and centrifugation were assayed  for free protein S 
(FPS) using a capture ELISA (32). Briefly, microtiter trays were 
coated overnight with rabbit anti-human PC antibody, blocked 
with powdered milk, and incubated with plasma (diluted 1:100 in 
PBS/0.1% Tween-20), peroxidase-conjugated  rabbit anti-serum PC, 
and OPD substrate. Assays  were performed in triplicate, and results 
were expressed as a percent of normal pooled plasma. 
Immunoperoxidase Studies.  Cryostat sections of PLP-fixed  renal 
biopsies and control  kidney specimens were  evaluated by im- 
munoperoxidase labeling with mAbs and rabbit polyclonal anti- 
bodies  to  thrombomodulin,  PC,  PC  activation  peptide, PS, 
thrombin, crosslinked fibrin, factor V, and yon WRlebrand factor. 
Antibodies were localized  using a two-layer  indirect immunoperox- 
idase method,  followed by incubation  with the  substrate, di- 
aminobenzidine, counterstaining  with hematoxylin, and mounting 
(26). Our previous studies have shown that cytokines such as TNF 
are poorly preserved in PLP-fixed  tissues, presumably  through failure 
of adequate crosslinking and immobilization of these smaN molec- 
ular weight glycoproteins, whereas they can be detected in corre- 
sponding acetone-fixed  sections prepared from the same tissues (6, 
25). Hence, cryostat sections of the unfixed portions of diagnostic 
renal biopsies that remained after immunofluorescent examination 
in six patients were fixed in acetone and evaluated using an anti- 
TNF mAb and a four-layer immunoperoxidase technique (26). 
Analysis of  Result~  Plasma  assays  and immunoperc0ddase  hbeling 
were performed and evaluated  routinely without knowledge of the 
patient's clinical course. Abnormal plasma results were confirmed 
by re-assay on at least one later occasion; interassay  variation was 
consistently  <10%. After decoding,  test results  were compared  with 
clinical and histopathologic data. Analysis was performed using 
the Statfast statistics program (Statsoft, Tulsa, OK). t test analysis 
of TNF results was determined using logl0-transformed data, or 
untransformed results in the case of  PC and PS data; similar results 
were found by nonparametric analysis using the Mann-Whitney 
U test. 
Particular attention was focused on: (a) the results of assays of 
samples taken around the time of proven rejection episodes, and 
conversely, (b) whether depressed plasma PC or FPS results, or raised 
plasma TNF levels, were demonstrable in the absence of clinicaUy 
detected rejection episodes. Rejection episodes  were determined by 
review of the medical records and the results of renal biopsy. A 
rejection episode was defined as a sudden (>40 #M/liter) and 
progressive rise in serum creatinine which, on renal biopsy, was 
associated with a standard histologic picture of acute interstitial 
and/or vascular  rejection (1), and which responded to increased  im- 
munosuppression. 
The intensity of immunoperoxidase labding was graded semi- 
quantitatively as trace (_+), weak (+), moderate (2 +), or strong 
(3 +), focusing especially  on the extent of residual labeling of en- 
dothelial cells using antibodies to thrombomodulin, as well as the 
distribution of TNF, PC, PS, and crosslinked fibrin. Intertubular 
capillaries, which are readily collapsed  and hence dif~cult to recog- 
nize in cryostat sections even in normal biopsies, and which may 
be depleted during severe  rejection (33), were identified  by staining 
of adjacent sections with PHM5 mAb. 
Results 
Patient Data.  The study group consisted of 25 consecu- 
tive adult renal transplant recipients,  who received kidneys 
from 21 cadaveric and four living related donors. Recipients 
consisted of 14 males  and 11 females, with a mean age of 
39 yr, (range 22-56 yr). Serial blood collection during the 
period of hospitalization, plus at regular follow up for 3 mo 
postdischarge, yielded 454 plasma samples; an average of 18 
_+  6 samples/patient were analyzed. 
Normal  Plasma  Data.  TNF  plasma  concentrations  in 
normal laboratory workers (n  --  10) were consistently low 
by both bioassay (43 +  25 pg/ml) and ELISA (28 _  21 pg/ml) 
methods, consistent with data from normal subjects reported 
by others (29). Hence, a cutoffwas established whereby TNF 
blood concentrations of <100 pg/ml were considered within 
the normal range (mean  _+  2 SD).  Similar results were de- 
tected using serum samples from the same patients, or when 
plasma samples were defibrinated by heating to 56~  fol- 
lowed by rapid cooling on ice and centrifugation. Analysis 
of individual normal plasma samples (mean _  SD) showed: 
PC antigen (PC-Ag), 104  _  14%; PC amidolytic activity, 
105  _+  9%;  total PS,  99  _+  10%;  and FPS,  103  _+  14%. 
Plasma Data during Acute Rejection.  TNF (mean  _+  SD) 
and creatinine data from 78 plasma samples collected during 
the course of 26 episodes of biopsy-confirmed acute cellular 
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Figure 1.  Cumulative serial data (mean  _+ SD) from blood specimens 
(n  =  76) showing alterations  in (A) TNF, (B) PC, and (C) FPS levels 
during 26 episodes of acute renal allografr rejection.  The day of rejection 
was defined as described in Materials and Methods; "p < 0.05,  ~  < 0.01, 
*"p  <  0.005,  ****p  <  0.001. 
rejection are summarized in Fig.  1 A.  TNF concentrations 
began to rise (390  _+  242 pg/ml, p <  0.01) 3 d before any 
substantial increase in serum creatinine levels, and peaked (2,426 
_  978 pg/ml) on the day of rejection. Plasma TNF concen- 
trations typically returned to basal levels within 2-3 d of this 
peak, in conjunction with high-dose, pulse steroids (n =  20) 
or OKT3 mAb (n  =  6) administration, whereas creatinine 
concentrations often took 7-10 d to approximate pre-rejection 
values. 
Rejection episodes were also associated with decreased levds 
of plasma PC (Fig. 1 B) and FPS (Fig. 1 C). PC-Ag concen- 
trations were mildly depressed 2-3 d before rejection ('~70%, 
p  <  0.05),  and reached a nadir of 49  _+  16%  ~  <  0.001) 
on the day of rejection (Fig. 1 B). Corresponding PC amido- 
Figure 2.  Correlations  between (,4) TNF and PC antigens,  (B) TNF 
and FPS antigens,  and (C) FPS and PC antigens  in 76 samples collected 
at the time of renal allograft  rejection. 
lytic activity estimations showed an almost identical pattern 
to PC-Ag results during acute rejection (results not shown). 
FPS levels dropped to 63  +_  8% ~  <  0.01)  1 d before rejec- 
tion, and were maximally depressed (43  _+ 10%) at the time 
of rejection (Fig. 1 C). Plasma TNF levels were significantly 
and inversely correlated with PC-Ag (r  =  0.86, p <  0.001; 
Fig.  2 A)  and FPS (r  =  0.71, p  <  0.005;  Fig.  2 B)  levels 
during rejection episodes.  PC-Ag and FPS results were directly 
correlated with each other (r  =  0.82, p <  0.001) (Fig. 2 C). 
Examples of serial plasma TNF,  PC,  and FPS data from 
patients with steroid-responsive or unresponsive acute rejec- 
tion are shown in Fig. 3, A  and B. The first patient, a 50-yr- 
old female who received a transplant from a living related 
donor, showed excellent renal function postoperatively.  How- 
ever, at 3 wk posttransplantation, her serum creatininejumped 
80/~M/liter  (day 0; Fig. 3 A), in conjunction with clinical 
features of rejection.  Renal biopsy on day 0  showed focal, 
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Representative examples of serial TNF, PC, and FPS levels 
during renal allograft rejection that was either (A) steroid responsive; or 
(/3) steroid unresponsive, necessitating treatment with OKT3  mAb for 
10 d. Composite graphs show TNF and creatinine data after proportionate 
reduction, as indicated in each panel. Mean _+ 2 SD indicates normal ranges 
for PC and FPS antigens. 
intense mononuclear cell infiltration around vessels and within 
interstitial areas, with intense tubular infiltration but only 
mild interstitial edema, no hemorrhages or thrombosis, and 
no evidence of vascular rejection; this pattern was reported 
as moderate interstitial rejection. The patient was treated for 
three consecutive days with intravenous steroids, and her renal 
function returned to normal. As seen in Fig. 3 A, TNF was 
detected 3 d before rejection (428 pg/ml), peaked on the day 
of rejection (4,089 pg/ml), and rapidly fell in association with 
steroid administration. Conversely,  PC and FPS levels were 
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59% and 66%, respectively, 3 d before rejection, fell to 42% 
and 40%, respectively, on day 0, but rose to within the normal 
ranges by day 3. 
The second patient, a 45-yr-old male recipient of a cada- 
veric donor kidney, demonstrates comparable results during 
steroid-unresponsive acute rejection (n  --  6).  This patient 
did well for the first  postoperative week but then, as cy- 
closporin was introduced, experienced gradually decreasing 
renal function over several days. A renal biopsy, performed 
to try and differentiate between possible rejection, cyclosporin 
toxicity, and acute tubular necrosis, showed a mixed picture 
of a very light accumulation of mononuclear cells at the cor- 
ticomedullary  junction, plus tubular dilatation and degener- 
ation, consistent with probably very mild interstitial rejec- 
tion and resolving acute tubular necrosis. However, 3 d later, 
despite intervening administration of three bolus doses of in- 
travenous steroids (days - 3,  - 2, and - 1; Fig. 3 B), the pa- 
tient's serum creatinine rose dramatically.  A biopsy on day 
0 showed mild interstitial rejection, with interstitial edema 
and a mixed mononuclear cell infiltrate that encroached upon 
tubular epithelium. OKT3 mAb therapy was undertaken for 
10 d, beginning on day 0, and the patient's clinical condition 
and renal function gradually returned to pre-rejection levels. 
In this patient, TNF levels remained at low, but significant, 
levels during the period of steroid administration (350-400 
pg/ml), rose to 4,539 pg/ml on day 0,  and then returned 
to normal by day 3, in association with OKT3 mAb adminis- 
tration. PC and FPS levels were maximally depressed to 41% 
and 35%  on days 0 and 1, respectively. 
A case of severe accelerated rejection occurred in a 35-yr- 
old male who received a transplant from a living related donor 
after a negative crossmatch. On the day after transplantation, 
this patient developed a fever of 38.7~  and a postoperative 
renal scan showed greatly decreased graft perfusion. The pa- 
tient's serum creatinine levels began to rise markedly (>100 
~M) each day, and a renal biopsy was performed on day 4 
posttransplantation. The biopsy showed severe vascular and 
interstitial rejection, with glomerular microthrombi, marked 
interstitial hemorrhages and mononudear cell infiltration,  ex- 
tensive vascular wall infiltration,  and widespread vascular IgM 
and C3 deposition. The patient, who had not received OKT3 
prophylactic therapy, was begun immediately on a 14-d course 
of OKT3 mAb, and renal function and clinical parameters 
returned to normal by day 14. Study results in this patient 
were preoperative:  TNF (109 pg/ml), PC (100%), and FPS 
(105%); day 1 posttransplantation: TNF (547 pg/ml), PC 
(92%), and FPS (103%); and day 4 (as OKT3 mAb was com- 
menced): TNF (718 pg/ml), PC (61%), and FPS (63%); TNF, 
PC, and FPS values returned to normal by day 7, and subse- 
quent days, posttransplantation. 
Nonrejection Plasma Data.  Resuhs of assays of TNF, PC-Ag, 
and FPS-Ag in all patients and normal controls are summa- 
rized in Table 1.  Rejection episodes  were associated  with 
significant elevation  of plasma TNF and depression of PC 
and FPS, in contrast to samples (n  =  349) collected during 
periods of stable renal function. Normal data were also found 
during episodes of cyclosporintoxicity, which was diagnosed 
in six patients based on elevated cyclosporin levels (> 800 Table  1.  Plasma TNF, PC, and FPS Levels in Renal  Transplant Recipients or Normal  Controls 
No.  samples  PC 
Group  (No.  individuals)  TNF  antigen  FPS antigen 
pg  /ml  ~  ~o 
Normal controls  35  (10)  43  _+  25  104  _+  14  103  _+  14 
Stable renal function  349  (25)  23  _+  25  117  _+  21  109  _+  16 
Acute rejection  78  (19)  1,128  •  838*  69  •  19'  59  +  18' 
CsA toxicity  16  (6)  76  •  31  131  •  32  115  +  26 
CMV infection  8  (2)  68  •  71  135  •  28  115  •  20 
Gram-negative sepsis  3  (1)  698  _+  269*  68  -+  24*  70  •  41s 
All data are mean _  SD.  TNF bioassay results are shown; acute rejection data include all samples from day -3 to day 3 of rejection,  as defined 
in Materials and Methods. 
* p <  0.01 compared with normal controls  or to transplant  recipients with stable renal function. 
p <  0.O05. 
Sp <  0.05. 
ng/ml), declining renal function, and response to reduction 
in the drug's dosage. Data were also normal in samples from 
two patients that were collected at the time of CMV infec- 
tion, documented by the presence of intranuclear inclusion 
bodies on renal biopsy and serologic evidence. A single pa- 
tient experienced an episode of Gram-negative septicemia, 
during which TNF, PC, and FPS data were abnormal and 
comparable with that seen in patients with acute rejection. 
Immunoperoxidase Data.  Histologic and immunofluores- 
cent evaluation of 23 consecutive biopsies confirmed the pres- 
ence of acute, predominantly interstitial, rejection with or 
without added vascular rejection. Unusual prominence of small 
vessel endothelial cells was remarked upon by the renal pa- 
thologist in the routine histologic reports of 18 of the biop- 
sies, consistent with the concept of endothelial activation 
during rejection. The results of immunoperoxidase localiza- 
tion of thrombomodulin, PC, PS, and fibrin are summarized 
in Table 2; no staining was seen using isotype-matched con- 
trol mAbs. 
Rejection was associated with a marked decrease or ab- 
sence of intertubular capillary thrombomodulin expression, 
in contrast to the dense labeling of all renal endothelium seen 
in kidneys collected for organ donation or removed for un- 
related,  therapeutic purposes. Such decreased staining was 
specific to the microvasculature,  since thrombomodulin was 
generally expressed at normal levels by adjacent arterioles or 
larger vessels and by glomerular capillaries. In one-third of 
cases, thrombomodulin  was also detected as interstitial labeling 
on and adjacent to the membranes of collections of mono- 
nuclear cells, especially macrophages, which were sites also 
rich in deposition of thrombin and crosslinked fibrin. Rejec- 
tion was also associated with interstitial and capillary deposi- 
tion of PC and PS (Table 2, Fig. 4), yon Willebrand factor, 
and, in five cams, factor V. Areas of heavy PC deposition gener- 
ally lacked corresponding labeling for PC activation peptide; 
the latter,  when present, was usually only detected within 
tubular lumina or the cytoplasm of tubular cells. Examples 
of paired staining for thrombomodulin and PC and PS be- 
fore and after treatment for acute rejection are shown in Fig. 
4, which demonstrates the dynamic nature of alterations  in 
Table  2.  Distribution of Thrombomodulin, PC, PC Activation Peptide, PS, and Fibrin in Renal Biopsies From Patients with Acute 
Renal Allografi Rejection vs. Normal Controls 
Group  No.  TM  PC  PC  activation peptide  PS  XL-fibrin 
Normal controls  4  3 + all endo  .... 
Mild rejection  7  _+  ITC  3 + i/s and ITC  •  i/s,  2 + tubules  2-3 + i/s and ITC  2 + i/s,  and ITC 
Moderate  rejection  13  •  or -ITC  2-3 + i/s and ITC  focal i/s,  2 +  tubules  2 + i/s and ITC  2-3 + i/s and ITC 
Severe rejection  3  -,  except large arteries  2 + i/s and ITC  3 + tubules  2 + i/s and ITC  2-3 + i/s and ITC 
Graded semiquantitatively  as described in Materials and Methods.  i/s, interstitial;  ITC, intertubular capillaries; XL-fibrin, crosslinked fibrin. 
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calization of thrombomodulin, PC, 
PS, and crosslinkecl  fibrin in sequen- 
tial renal biopsies from a patient 
with acute rejection. Panels on the 
left are from a biopsy at day 14 post- 
transplantation that showed  mild to 
moderate  interstitial  rejection; 
plasma  TNF  was  1,560 pg/ml, 
PCoAg -  52%, and FPS -  44%. 
Panels on the right are from a bi- 
opsy  taken 10 d htm, after  treatment 
of rejection with methylpr~lniso- 
lone, which showed  resolving  inter- 
stitial rejection; plasma TNF was 
<20 pg/ml,  PC-Ag  -  94%, and 
FPS  -  89%. (a and b) Intertubular 
capiUaries  within each  transplant bi- 
opsy are labeled  with PHM5 mAb. 
(c and d) There is essentially  no ex- 
pression of thrombomndulin on in- 
tertubular capillaries during rejec- 
tion, whmas after  rejection  therapy, 
the  interstitial  mononuclear  cell 
infiltrate has decreased and inter- 
tubular capillaries  again show label- 
ing for thrombomodulin. (e and  f) 
PC deposition is noted over  capil- 
laries and adjacent interstitial areas 
daring rejection, as is (g and h) PS, 
whereas both are cleared  on follow- 
up biopsy. (i and  j) Widespread in- 
terstitial deposition of crosslinked 
fibrin is present during rejection, 
but not at resolution 10 d later. He- 
matoxylin counterstain, PLP fixa- 
tion,  indirect immunoperoxidase, 
x300. 
thrombomodulin expression and deposition of PC, PS, and 
fibrin. 
AU six patients with acute rejection in whom unfixed renal 
biopsy material was available showed staining for TNF. TNF 
was typically demonstrated as dense labeling of interstitial 
mononuclear cells and renal microvasculature (Fig. 5), whereas 
control sections from normal  kidneys were unstained. 
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Discussion 
This study was based on the concept that since rejection 
is an immunologic event, ~.atures of immune activation should 
not only be demonstrable, but indeed might be of use in the 
early detection and differential diagnosis of episodes of acute 
renal failure in the early posttransplant period. We have pre- 
viously shown that human renal transplant  rejection is as- Figure 5.  Immunoperoxidase detection of TNF within a renal biopsy 
of patient with acute cellular rejection showing dense labeling of large 
numbers of interstitial mononuclear cells and small vessel endothelium. 
Hematoxylin counterstain, acetone  fixation,  x400. 
sociated with intragraft mononudear cell activation, as reflected 
by mononuclear cell expression of IL-2R and procoagulant 
antigens  (4); these results were subsequently  confirmed by 
Ser6n et al. (34). However,  the development  of faster, less 
invasive tests for detection of rejection would greatly facili- 
tate the clinical management of patients  who present  such 
diagnostic dilemmas as the need to distinguish acute rejec- 
tion from cyclosporin toxicity,  viral infection  or, on occa- 
sions, slowly resolving acute tubular necrosis. Careful studies 
by Colvin et al. (11) indicated that serial monitoring of pe- 
ripheral blood II.-2R concentrations appeared to be of diag- 
nostic value in the detection of kidney rejection, and this ap- 
proach is under evaluation  in many centers worldwide. Though 
obviously relevant to the practical diagnosis of rejection, such 
measurements do not directly improve our understanding of 
the precise molecular mediators of graft rejection. However, 
Maury and Teppo (8) reported increased serum levels  of TNF 
during acute rejection, as well as during infection, indicating 
that TNF might be a clinically relevant mediator of rejection 
whose actions could be analyzed in vivo and in vitro.  No 
data were presented in the latter study concerning TNF levels 
during episodes of eyclosporin toxicity, and reservations about 
the accuracy of'diagnosis of rejection episodes arose since re- 
jection was diagnosed only upon clinical criteria and limited 
fine needle aspiration  studies. We therefore undertook: (a) 
a prospective, controlled study of the significance of TNF 
monitoring in renal transplant  recipients, and (b) given the 
potent effects  of TNF on endothelial cells in vitro, and previous 
evidence of macrophage and endothelial procoagulant expres- 
sion during rejection (4), evaluation of whether TNF produc- 
tion during rejection was associated with effects on intragraft 
thrombomodulin/PC/PS anticoagulant system expression. 
Plasma levels of TNF were reproducibly elevated in renal 
transplant  recipients during episodes of biopsy-proven acute 
rejection, typically rising 2-3 d before elevation of serum cre- 
atinine data, and returning to normal with successful  antirejec- 
tion therapy. Such  rejection-associated  increases  in plasma TNF 
were not simply attributable to OKT3 mAb-induced release 
(35),  since plasma TNF levels rose before OKT3 mAb ad- 
ministration, and were also apparent in steroid-responsive  cases 
not requiring OKT3 therapy. Conversely, TNF levels were 
not elevated during episodes of cyclosporin toxicity or CMV 
infection, but were elevated during the sole case of bacterial 
sepsis. Septicemic patients  generally  show marked hemo- 
dynamic alterations  and positive blood cultures,  and so are 
not usually difficult to discriminate from patients with acute 
rejection. Hence, given the good correlation observed between 
bioassay and ELISA methods, indicating the presence of both 
immunoreactive and biologically  active TNF,  these results 
show that monitoring of serial TNF levels  in peripheral blood 
by ELISA is a rapid, useful, and practical aid to the early di- 
agnosis of acute kidney rejection, and its discrimination from 
other causes of declining renal function and mononuclear cell 
infiltrates,  such as episodes of cyclosporin toxicity  or viral 
infection.  Though the source of TNF was not identified in 
the current study, our studies in experimental  rat renal (7) 
and cardiac (25) transplant  models have shown that TNF is 
produced by graft infiltrating mononuclear cells, especially 
macrophages, during rejection, and spills over to be detect- 
able within the peripheral blood, though at considerably  lower 
concentrations than within corresponding graft homogenates. 
PC and PS concentrations in plasma samples from renal 
transplant recipients were determined since we had previously 
shown that rat cardiac and renal transplant rejection was as- 
sociated with intragraft production of TNF and widespread 
PC and PS deposition (25), resulting in low concentrations 
of PC and PS in corresponding blood samples. Moreover, 
preliminary screening of blood samples from patients  with 
renal, cardiac, or liver transplant rejection showed depression 
of PC levels during rejection episodes, consistent  with this 
concept of intragraft consumption of anticoagulant molecules 
during rejection. In the current study, we found that plasma 
PC and FPS concentrations in patients with stable renal func- 
tion were comparable with concentrations in normal con- 
trols,  but fell to <50%  of normal during rejection,  in in- 
verse correlation to rising plasma TNF levels. Like TNF, PC 
and FPS data were also normal during episodes of cyclosporin 
toxicity or CMV infection, hut fell significantly during bac- 
terial sepsis, as previously reported (36). These findings indi- 
cate that acute rejection of human renal transplants is associated 
with an acquired deficiency of PC and FPS, which may con- 
tribute to the increased  incidence of venous thromboembolism 
in renal transplant  recipients (37, 38). Recently, Sorensen et 
88  Tumor Necrosis Factor and Anticoagulant Molecules  during Graft Rejection al. (39) also reported that in at least 7 of 11 renal transplant 
recipients, PC coagulant activity was lowered in parallel with 
increasing creatinine concentrations and development of clinical 
graft rejection; however, no data were presented on PS or 
TNF  levels,  nor were any renal biopsy data provided. 
Immunohistologic studies showed that acute rejection was 
associated with local expression of TNF and marked reduc- 
tion of endothelial labeling for thrombomodulin. Such reduc- 
tion was not simply due to destruction of renal microvas- 
cular cells during severe rejection, as previously noted (33), 
since intertubular capillaries were still readily detected in se- 
quential sections using PHM5 mAb (Fig. 4). Decreased throm- 
bomodulin expression was largely confined to intertubular 
capillaries, arterioles, and venules, since endothelial cells of 
adjacent larger vessels continued to show strong labeling with 
antithrombomodulin antibodies during rejection episodes, and 
thrombomodulin microvascular expression rapidly returned 
to normal as antirejection immunosuppressive therapy was 
implemented. The association of rising TNF levels in vivo 
during rejection and decreased thrombomodulin expression 
within graft capillaries, followed by return of both throm- 
bomodulin and TNF to normal prerejection concentrations 
in response to therapy, are consistent with, and reinforce the 
biologic relevance of, the effects of TNF on human endothelial 
cells previously documented only in vitro  (16). 
Several  consequences  of  decreased  intragraft  thrombo- 
modulin expression are likely. As reviewed by Esmon (17), 
thrombomodulin  normally  binds  thrombin,  blocking  its 
ability to clot fibrinogen. In addition,  thrombin bound to 
thrombomodulin functions as an anticoagulant by catalyzing 
the conversion of PC to activated PC, a step involving pro- 
teolytic release of a low molecular activation peptide from 
the light chain of PC. Activated PC, in the presence of its 
cofactor PS, inactivates factors Va and VIIIa, and promotes 
fibrinolysis by decreasing endothelial plasminogen activator 
inhibitor activity. The current findings are consistent with 
both local activation and swamping of this thrombomod- 
ulin/PC/PS pathway during rejection. Considerable intragraft 
PC had undergone activation, as suggested by the differences 
in labeling using antibodies reactive with both PC and acti- 
vated PC versus that of a mAb specific to the low molecular 
weight PC activation peptide. Moreover, widespread PC and 
PS deposition were noted, to the extent that circulating levels 
of these molecules were temporarily deficient during rejec- 
tion episodes. Hence, the widespread, dense endothelial and 
interstitial depositions of thrombin and fibrin detected during 
rejection are likely to reflect both  the increased intragraft 
procoagulant activity, as previously documented (4), and the 
currently  observed  failure  of  the  thrombomodulin  an- 
ticoagulant pathway; both of which can be mediated, at least 
in part, by TNF. 
By extrapolation from its known actions in vitro (14), local 
production of TNF has a number of potential consequences 
for the immunobiology of rejection. TNF may cause direct 
injury to adjacent cells, facilitate mononuclear activation and 
production of cytokines such as Ibl and I1,-6, and upregulate 
endothelial expression of leukocyte adhesion molecules and 
MHC  class I target antigen expression. However, the cur- 
rent results implicate TNF in disruption of the normal an- 
ticoagulant state of intragraft endothelium, resulting in the 
widespread intragraft fibrin deposition, which is one of the 
hallmarks of kidney rejection (37, 40).  Such fibrin deposi- 
tion and associated production of fibrin degradation prod- 
ucts can facilitate attraction and activation of macrophages, 
retard interstitial microcirculatory blood flow, and thereby 
directly impair renal function. As a corollary, allograft rejec- 
tion is also associated with an acquired deficiency of PC and 
FPS in peripheral blood samples, which may contribute to 
the increased rate of thromboembolism found in renal trans- 
plant recipients (37, 38). Together, these findings provide a 
rationale for the monitoring of blood TNF,  PC,  and FPS 
levels as guides to the early detection and differential diag- 
nosis of human renal allograft  rejection. 
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